



OPEN

Performance of EasyBreath Decathlon Snorkeling mask for delivering continuous positive airway pressure

Alberto Noto^{1,2,✉}, Claudia Crimi³, Andrea Cortegiani^{4,5}, Massimiliano Giardina⁶, Filippo Benedetto⁷, Pietro Princi², Annalisa Carlucci^{8,9}, Lorenzo Appendini¹⁰ & Cesare Gregoretti^{4,11}

During the COVID-19 pandemic, the need for noninvasive respiratory support devices has dramatically increased, sometimes exceeding hospital capacity. The full-face Decathlon snorkeling mask, EasyBreath (EB mask), has been adapted to deliver continuous positive airway pressure (CPAP) as an emergency respiratory interface. We aimed to assess the performance of this modified EB mask and to test its use during different gas mixture supplies. CPAP set at 5, 10, and 15 cmH₂O was delivered to 10 healthy volunteers with a high-flow system generator set at 40, 80, and 120 L min⁻¹ and with a turbine-driven ventilator during both spontaneous and loaded (resistor) breathing. Inspiratory CO₂ partial pressure (PiCO₂), pressure inside the mask, breathing pattern and electrical activity of the diaphragm (EAdi) were measured at all combinations of CPAP/flows delivered, with and without the resistor. Using the high-flow generator set at 40 L min⁻¹, the PiCO₂ significantly increased and the system was unable to maintain the target CPAP of 10 and 15 cmH₂O and a stable pressure within the respiratory cycle; conversely, the turbine-driven ventilator did. EAdi significantly increased with flow rates of 40 and 80 L min⁻¹ but not at 120 L min⁻¹ and with the turbine-driven ventilator. EB mask can be safely used to deliver CPAP only under strict constraints, using either a high-flow generator at a flow rate greater than 80 L min⁻¹, or a high-performance turbine-driven ventilator.

Hospitals and physicians worldwide are facing a new health emergency as a consequence of the coronavirus diseases 2019 (COVID-19) pandemic¹ that has spread enormously worldwide², placing an extraordinary demand on the health-care systems. Approximately 30% of hospitalized patients with COVID-19 develop acute hypoxemic respiratory failure (AHRF) requiring oxygen and noninvasive respiratory support (NRS). About 5% of them require invasive mechanical ventilation (IMV) and intensive care unit (ICU) admission^{3–5}.

Healthcare organizations have proactively implemented several strategies to supply shortages of equipment as demand surges, rationing life-saving treatments such as using shared mechanical ventilation⁶, establishing ventilator lottery or ventilator triage policies^{7,8}, and increasing the use of NRS⁹. To address the high demand for NRS equipment exceeding the capacity, Food and Drug Administration issued an emergency policy allowing the use of home respiratory devices, such as Continuous Positive Airway Pressure (CPAP), as an alternative to life-saving ventilators¹⁰.

¹Division of Anesthesia and Intensive Care, Department of Human Pathology of the Adult and Evolutive Age “Gaetano Barresi”, University of Messina, Policlinico “G. Martino”, Via Consolare Valeria, 1, 98100 Messina, Italy. ²IPCF-CNR, Institute for Chemical and Physical Processes, National Research Council, Messina, Italy. ³Respiratory Medicine Unit, “Policlinico-Vittorio Emanuele San Marco” University Hospital, Catania, Italy. ⁴Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), University of Palermo, Palermo, Italy. ⁵Department of Anesthesia Intensive Care and Emergency, Policlinico Paolo Giaccone, Palermo, Italy. ⁶Anesthesia and Intensive Care, Policlinico “G. Martino”, Messina, Italy. ⁷Unit of Vascular Surgery, Department of Biomedical, Dental Sciences and Morphofunctional Imaging, Policlinic “G. Martino”, University of Messina, Messina, Italy. ⁸Department of Medicina e Chirurgia, Università Insubria Varese-Como, Varese, Italy. ⁹Pulmonary Rehabilitation Unit, Istituti Clinici Scientifici Maugeri, Pavia, Italy. ¹⁰ASL CN1, S.S.D. Fisiopatologia Respiratoria, Ospedale di Saluzzo, Saluzzo, CN, Italy. ¹¹G. Giglio Foundation, Cefalù, Italy. ✉email: alberto.noto@unime.it

CPAP level (cmH ₂ O)	40 L min ⁻¹ Mean (SD)	80 L min ⁻¹ Mean (SD)	120 L min ⁻¹ Mean (SD)	Astral 150 Mean (SD)	p value
5	5 (0.9)	1.2 (0.7)	0 (0)	0 (0)	<0.01
10	6.5 (1.3)	1.9 (0.8)	0 (0)	0 (0)	<0.01
15	7 (1.5)	3.2 (1.4)	0 (0)	0 (0)	<0.01

Table 1. Inspiratory CO₂ partial pressure at different flow rate and PEEP level. CPAP continuous positive airway pressure, SD standard deviation, PEEP positive end expiratory pressure, Astral 150 turbine-driven ventilator. p value ANOVA for repeated measures (same CPAP level with different flow).

The need to ensure the availability of the highest possible number of CPAP devices also led a group of engineers from northern Italy to build an “emergency ventilator mask”, converting full face snorkeling masks into interfaces that can be used to apply CPAP therapy¹¹. Nevertheless, innovative and potentially life-saving products not previously tested and approved for clinical use can cause serious adverse effects.

Thus, the present study aimed to assess the technical performance of a modified commercial surface snorkeling mask EasyBreath (EB mask), (Decathlon, Villeneuve-d’Ascq, France) that has been used in COVID-19 patients for delivering CPAP. The aim of this study was to test its use during different gas mixture supplies, evaluating the stability of pressure generated and the amount of carbon dioxide (CO₂) rebreathing inside the EB mask during spontaneously and resistive loaded breathing in healthy volunteers.

Results

Ten healthy volunteers (eight males and two females), with age comprised between 27 and 45 years old and a mean body mass index (BMI) of 24 kg/m² completed the study. None of the subjects complained about discomfort or fogging of the interface.

The FiO₂ delivered during CPAP with the flow generator was between 31 and 34%, depending on the flow/PEEP combination. During CPAP delivered with the turbine-driven ventilator, the FiO₂ ranged from 30 to 35%.

The PiCO₂ ranged from 0 to 7 mmHg, depending on the flow/CPAP level combination used (p < 0.01, ANOVA for repeated measurements), as shown in Table 1. The highest PiCO₂ was recorded at 40 L min⁻¹ of fresh gas flow with CPAP 15 cmH₂O and it decreased progressively to 0 (undetectable) as the fresh gas flow increased up to 120 L min⁻¹ or using the turbine-driven ventilator, independently of the CPAP level.

The pressures inside the mask at different flows/PEEP are shown in Fig. 1. Target CPAP was not achieved when the oxygen-driven flow generator delivered 40 L min⁻¹. Only the highest flow tested (120 L min⁻¹) allowed the achievement of all the CPAP levels tested (5, 10, 15 cmH₂O), even if some over-treatment was obtained at CPAP 5 and 10 cmH₂O (+119% and +35%, respectively). By contrast, the turbine-driven ventilator allowed the maintenance of target CPAP levels throughout the protocol.

Supplementary Table S2 also shows actual CPAP partitioned between the inspiratory and expiratory phase, as referenced to target CPAP. Only the turbine ventilator succeeded in keeping the actual CPAP level close to its target value both at end-expiration and at end-inspiration for all the CPAP levels tested, the pressure difference between end-inspiration and end-expiration being maintained within 2 cmH₂O. Statistically and clinically worse was the performance of the high-flow generator in this task. As a matter of fact, at a flow of 40 L min⁻¹, neither end-inspiratory nor end-expiratory pressures reached the target CPAP. In contrast, at 80 and 120 L min⁻¹, the actual pressure was above its target level at end-expiration and below it at end-inspiration, with the difference between these two conditions being well above 2 cmH₂O. Similar results were obtained for both loaded and unloaded breathing (Supplementary Table S2).

The respiratory pattern (flows, volume, and respiratory timing) and the EAdi recorded at baseline and at different experimental conditions, with and without the use of the resistor, are shown in Supplementary Table S1 and Fig. 2. In comparison to baseline, minute ventilation remained stable with the CPAP mask at any level of pressure applied during unloaded breathing. By contrast, it significantly decreased during loaded breathing because of a significant reduction of tidal volume. Respiratory rate remained constant throughout the protocol (Supplementary Table S1).

Diaphragmatic electrical activity increased with any CPAP level compared to baseline, either in terms of EAdi Insp_{AUC} and EAdi/V_T (Fig. 2). During loaded breathing, EAdi increased by a similar amount in all the conditions tested.

Discussion

The present study showed that the use of a modified EB mask coupled with a high-flow generator: (1) induces substantial CO₂ rebreathing when set at a flow rate below 80 L min⁻¹, (2) fails to achieve CPAP levels higher than 5 cmH₂O if set at a flow rate of 40 L min⁻¹ and (3) increases diaphragm’s electrical activation (hence, diaphragmatic energy expenditure) due to pressure instability along the respiratory cycle. These adverse effects disappear using high flows (> 80 L min⁻¹) or a high-performance turbine-driven ventilator set in CPAP mode.

The use of repurposed devices to fend off the shortage of ventilators during the current COVID-19 pandemic, without prior evidence of efficacy, is an issue of increasing concern¹². Manufacturers can market medical devices without proof of their effectiveness, especially in urgent unusual circumstances like the COVID-19 pandemic¹³. Indeed, the emergency may force clinicians to adopt unregistered interfaces, such as the popular EB mask, to deliver ventilatory support to patients, with little or no prior tests of performance. To the best of our knowledge, this is the first study that fills this knowledge gap after introducing the modified EB mask for CPAP delivery.




Figure 1. Pressure recorded inside the mask. Upper whiskers represent the average expiratory peak pressure at end-expiration. Lower whiskers represent the mean pressure at the average inspiratory peak pressure at end-inspiration; circles represent the mean pressure computed throughout the respiratory cycle; redline represents the set CPAP level.




Figure 2. Electrical diaphragm effort. $EAdi/V_T$, electrical diaphragm activity area of the inspiratory phase normalized for the tidal volume (V_T); $EAdi\ Insp_{AUC}$, electrical diaphragm activity area of the inspiratory phase.

Using CPAP in AHRF has the principal aim to improve gas exchange, increasing the end-expiratory lung volume (EELV) and avoiding the inspiratory elastic threshold-load imposed by the increased EELV¹⁴, also when applied non-invasively^{15,16}. However, some interfaces can provoke CO₂ rebreathing if misused, thus impairing treatment effectiveness¹⁷.

CO₂ rebreathing. EB mask has a wide dead-space (about 800–900 mL), and thus, given a fixed CO₂ production, it requires high flows to wash-out the exhaled CO₂ completely, as with other high dead-space interfaces¹⁷.

CPAP flow rate of 120 L min⁻¹ or flows guaranteed by a high-performance turbine-driven ventilator completely flushed out CO₂. Remarkably, if the gas flow is not high enough to generate pressures able to keep the PEEP valve open, the CO₂ wash-out is not guaranteed. Thus, in case of emergency use of the EB mask, the first caveat is to use very high flows of fresh gas (about fourfold the peak inspiratory flow) in the circuit, whatever its source.

Effectiveness in achieving target CPAP. An ideal CPAP system, by definition, should provide a target positive airway pressure through the respiratory cycle to improve alveolar recruitment and gas exchange. Conversely, our data showed that although the pressure inside the EB mask never dropped below zero during the inspiratory phase, it always remained far below the set CPAP level when using a fresh gas flow of 40 L min⁻¹, indicating that at this target inspiratory flow the PEEP valve was closed and, thus, malfunctioning. Such low driving flows should be avoided and properly increased to maintain the airflow through the PEEP valve throughout the respiratory cycle (driving flow greater than 80 L min⁻¹ in the present study). On the other hand, during the expiratory phase, the pressure level recorded at the highest rate of fresh gas flow (120 L min⁻¹) overcame the set CPAP level, at least at 5 and 10 cmH₂O, potentially generating an undue increase in end-expiratory lung volume. This is probably due to the performance of the PEEP valve at high flow (120 L min⁻¹) since when the total flow (fresh gas flow + expiratory flow) exceeds the capacity of the PEEP valve, pressure becomes “flow-dependent”¹⁸. Fresh gas flow of 80 L min⁻¹ performed in the middle, overcoming the set pressure of 5 cmH₂O and under-assisting at the target CPAP of 15 cmH₂O.

Mechanical ventilators are the most sophisticated devices to administer CPAP. However, old devices performed worse than high flow generators in delivering stable CPAP levels, mainly because of the demand-valve technology¹⁹. The newer generation of ventilators has complex flow algorithms that allow for a more aggressive flow modulation and delivery flows using single circuits with intentional leaks designed to stabilize airway pressure and lessen the imposed work of breathing¹⁵. This was the case in our study when CPAP was delivered with the turbine-driven ventilator provided with an intentional leak circuit (EB mask + turbine-ventilator + single circuit + intentional leak), where we recorded a stable pressure at any level of target CPAP tested.

Diaphragmatic activity and effort. An ideal CPAP system should provide a constant positive airway pressure throughout the respiratory cycle to avoid negative effects on the work of breathing^{20,21} since large pressure swings around the set PEEP level are associated with increased respiratory efforts²². Our study showed that end-inspiratory to end-expiratory pressure swing was clinically relevant (above 3 cmH₂O) at all set levels of CPAP and flows when using the high flow generator with a flow rate lower than 80 L min⁻¹. We observed this phenomenon notwithstanding the presence of a reservoir bag and a threshold PEEP valve in the CPAP circuit that should maintain the pressure stable, whatever is the flow passing through it. Pressure swings occurring across target CPAP levels imply wasted patients' respiratory effort spent against CPAP device, ineffective in producing flow and volume¹⁹. As a matter of fact, EAdi inspiratory activity and, hence, diaphragmatic effort²³ increased with CPAP application compared to baseline in all the study conditions (with or without resistive loading) when high flow CPAP generator delivered flows of 40 and 80 L min⁻¹. This result confirms previous data showing increased work of breathing during CPAP application²⁴, and suggesting a suboptimal performance of high flow CPAP generators^{18,25}.

EAdi increase can be due to CPAP system-induced extended workload, on a CO₂ rebreathing-induced increase of respiratory drive, or a combination of both. The inspiratory EAdi-time product (EAdi InspAUC) increased by 45% during CPAP application and only 35% when normalized for V_T, implying that both the above-quoted mechanisms contributed to the overall increase of EAdi activity during EB mask CPAP delivery, compared to spontaneous breathing. The increase of diaphragmatic electrical activity (and effort) disappeared during both CPAP set at the highest flow (120 L min⁻¹) and delivered by the turbine ventilator showing that considering these constraints is crucial in EB mask emergency use.

This study should be a warning sign against the indiscriminate use of tools to deliver noninvasive respiratory support without rigorous performance tests.

Strengths and limitations. The main strength of our study is the rigorous evaluation of several parameters of performance (i.e. PiCO₂, Pmask, EAdi) at three different levels of flow, recreating the setup used in clinics for noninvasive ventilatory support in COVID-19 patients.

The present study has several limitations. First, this was a proof-of-concept study performed in healthy volunteers; therefore, it may not reflect the dynamic nature of ventilation parameters during severe acute respiratory syndrome. However, simulating loaded breathing, we partially overcame this limitation. Second, we did not compare the new device against a ‘gold standard’. Thus, up to now, it is only clear that the EB mask works properly only under strictly controlled conditions. Still, it is impossible to state whether it is inferior/superior to reference interfaces. Finally, the PiCO₂ was stable during the conditions tested, but the recordings lasted only 2 min each. Therefore, we cannot ensure that these values would have remained stable for a longer period.

Conclusion

The modified Decathlon's EB mask should be used for emergency use to deliver CPAP only under strict constraints, using a high flow generator at a flow rate greater than 80 L min⁻¹, or with a high-performance turbine-driven ventilator.




Figure 3. Experimental setup. CPAP continuous positive airway pressure, PEEP positive end expiration pressure.

Methods

Study design. We designed a physiological study involving ten healthy volunteers recruited among physicians at the Department of Anesthesia and Critical Care, Policlinico "G. Martino," University of Messina, Italy, in June 2020. The study was approved by the Ethics committee of Policlinico G. Martino, Messina, Italy (32-30 27/05/2020). All the study participants provided written informed consent. All methods were performed in accordance with relevant guidelines and regulations.

Experimental set-up and study devices. The experimental set-up is illustrated in Fig. 3. We used a modified Decathlon's EasyBreath (EB mask) surface snorkeling mask (Decathlon, Villeneuve-d'Ascq, France) as a full-face mask to deliver CPAP. The original valve set on the chin was modified to be permanently closed, allowing all exhaled air to be evacuated through the two lateral channels of the mask to the top of the snorkel²⁶. Unlike conventional interfaces used in clinical practice, this mask has two different compartments inside; the upper one for the eyes, dedicated to the vision, and the lower one for the mouth and nose, dedicated to the breathing. The original EB mask snorkel was replaced with a 3D printed adaptor, the Charlotte valve, patented by ISINNOVA (Brescia, Italy), to connect the mask to an oxygen-driven flow generator. This valve has an inlet line connected to the oxygen and an outlet line connected to a threshold resistor [Positive End Expiratory Pressure (PEEP) valve], as shown in Supplementary Fig. S1. An HEPA filter (DAR™ Mechanical Filter Compact) was added to a breathing circuit of 120 cm. FiO_2 was kept constant with a range of 30–35% (measured with oxy-sensor inside the mask), to avoid extra variability to the experiment.

The internal volume was measured by filling the mask with water when applied to the volunteers' face, as previously described²⁷, and amounted to 880 ± 11 mL.

To allow measurements, the experimental setting included the following items (Fig. 3):

1. a pneumotachograph (V.T. mobile; Fluke Biomedical, Everett, WA, USA) to measure ventilatory airflow, connected with a serial interface to a laptop for recording (V.T. for Windows Software version 2.01.07, Fluke Biomedical, Everett, WA, USA);
2. a side-stream capnometer (CO2SMO plus; Novamatrix Medical System, Wallingford, Connecticut, USA) to measure inspiratory carbon dioxide tension (PiCO_2);
3. a dedicated nasogastric tube with a built-in multiple array esophageal electrode (Edi catheter) to monitor diaphragm activity¹⁴. It was connected to a Servo-I ventilator (Getinge, Solna, Sweden), equipped with Neurally Adjusted Ventilatory Assist (NAVA) (Getinge, Solna, Sweden), linked through a serial interface to a laptop with dedicated software (Servo-tracker version 4.2, Getinge, Solna, Sweden).
4. a pressure transducer (coupled to the V.T. mobile, through an auxiliary port) to measure the pressure inside the mask (P_{mask}) connected to the laptop for recording.




Figure 4. Matlab automatic EAdi analysis. $EAdi$ electrical diaphragm activity, $EAdi_{max}$ peak electrical diaphragm activity, $EAdi_{min}$ electrical diaphragm activity, $EAdi Insp_{AUC}$ electrical diaphragm activity area of the inspiratory phase, $EAdi Tin$ inspiratory time derived from electrical diaphragm activity, $EAdi Ttot$ total respiratory time derived from electrical diaphragm activity.

All the instruments underwent testing and calibration according to the manufacturers' specifications before performing all the measurements.

Measurements and recordings. Based on the experimental set-up, the following variables were measured: (1) $PiCO_2$; (2) Minute ventilation; (3) P_{mask} ; (4) electrical diaphragm activity (EAdi).

Each volunteer was studied placed comfortably in a semi-recumbent position and performed all the tests on the same day in random order. Volunteers were first allowed to adapt to CPAP breathing before the recordings.

At baseline, two, 120 s each, recordings of breathing pattern and EAdi were carried out without the mask. The first one during quiet unloaded breathing, and the second while breathing through an inline resistor (connected to the mouthpiece) made with an endotracheal tube connector with an inner diameter of 5 mm, to simulate an increase of respiratory load.

After tightly fitting to the volunteers' face the modified EB mask¹¹, leaks were minimized by sealing the mask chin valve around all measurement lines. Two sets of measurements were performed while delivering CPAP with two different systems:

1. a CPAP flow generator (Whisperflow 2, Respironics), connected to the 3D printed Charlotte valve¹¹ attached to the mask. A reservoir bag inserted in the inspiratory line was used to minimize airway pressure variations. An adjustable PEEP valve (Ambu, Denmark) added to the Charlotte valve's expiratory port provided the PEEP level. $PiCO_2$, P_{mask} , flow lines, and the Edi catheter were inserted into the mask through the sealed chin valve (Fig. 3). CPAP was set at three different flow rates (40, 80, 120 L min^{-1}) and for each flow, three different PEEP levels were employed (5, 10, 15 cmH_2O), with and without the resistor in place (*load*);
2. a turbine-driven home care mechanical ventilator (Astral 150, Resmed, San Diego, USA) set in CPAP mode at three different PEEP levels: 5, 10, 15 cmH_2O . CPAP was administered with a single limb vented configuration with an intentional leak (a tube connector with an inner diameter of 5.5 mm) placed on the Charlotte valve's expiratory port. Low-pressure oxygen was provided to the turbine-driven ventilator through a dedicated port in order to obtain the same FiO_2 used to drive the flow generator.

The total length of breathing circuit was 120 cm. A 120 s-trial was recorded for each session for off-line analysis. No instructions were given to the subjects regarding the breathing pattern to adopt.

Data analysis. A Matlab (version 9.7.0.1190202, The MathWorks Inc., Natick, Massachusetts, USA) automatic procedure was developed to find maximal and minimum EAdi (Fig. 4) and pressure for each breath. The EAdi-time product, measured as the EAdi curve area from the beginning to the end of an inspiratory cycle ($EAdi Insp_{AUC}$), was calculated (Fig. 4). The $EAdi Insp_{AUC}$ was then normalized for the tidal volume (V_T), ($EAdi / V_T$).

Average end-expiration and end-inspiration peak pressures were calculated for every recording session. The same was also done for the $EAdi_{max}$, $EAdi_{Insp_{AUC}}$, and $EAdi/V_T$. For each recording session, the average delta pressure inside the mask at the end-expiration ($\Delta P_{mask\ Exp} = P_{mask\ end-expiratory} - CPAP\ Level$) and end-inspiration ($\Delta P_{mask\ Insp} = P_{mask\ end-inspiratory} - CPAP\ Level$) were computed.

The distribution of each continuous variable was initially tested with the Shapiro–Wilk test for normality. Results are expressed as mean \pm SD when normally distributed, otherwise as median and interquartile range. Based on preliminary measurements, we estimated that 10 healthy subjects were necessary to detect, with a 0.8 power, a significant difference ($\alpha = 0.05$) on airway pressure drop during inspiration ($\Delta P_{mask\ Insp}$). Comparisons of ΔP_{mask} at different flows and for each CPAP level were assessed using the analysis of variance (ANOVA) for repeated measures. The statistical analysis was performed using (SPSS 24, IBM) software. A p value < 0.05 was considered significant.

Received: 29 October 2020; Accepted: 24 February 2021

Published online: 10 March 2021

References

1. WHO. *Coronavirus disease (COVID-2019) Situation Report 2020*. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen> (2020).
2. *Dashboard by the center for systems science and engineering (CSSE) at Johns Hopkins University*. <https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6> (2020).
3. WHO. *Coronavirus disease 2019 (COVID-19) situation report—38*. World Health Organization, Geneva. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200227-sitrep-38-covid-19.pdf?sfvrsn=9f98940c_2 (2020).
4. Huang, C. *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* **395**, 497–506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5) (2020).
5. Wang, D. *et al.* Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* <https://doi.org/10.1001/jama.2020.1585> (2020).
6. Herrmann, J., Fonseca da Cruz, A., Hawley, M. L., Branson, R. D. & Kaczka, D. W. Shared ventilation in the era of COVID-19: A theoretical consideration of the dangers and potential solutions. *Respir. Care* <https://doi.org/10.4187/respcare.07919> (2020).
7. Silva, D. S. Ventilators-by-lottery: The least unjust form of allocation in the COVID-19 pandemic. *Chest* <https://doi.org/10.1016/j.chest.2020.04.049> (2020).
8. Emanuel, E. J. *et al.* Fair allocation of scarce medical resources in the time of Covid-19. *N. Engl. J. Med.* **382**, 2049–2055. <https://doi.org/10.1056/NEJMsb2005114> (2020).
9. Crimi, C. *et al.* Noninvasive respiratory support in acute hypoxemic respiratory failure associated with COVID-19 and other viral infections. *Minerva Anestesiol.* <https://doi.org/10.23736/S0375-9393.20.14785-0> (2020).
10. FDA, U. S. *Enforcement Policy for Ventilators and Accessories and Other Respiratory Devices During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency*. <https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/coronavirus-disease-2019-covid-19> (2020).
11. Mauri, T. *et al.* Physiologic effects of high-flow nasal cannula in acute hypoxemic respiratory failure. *Am. J. Respir. Crit. Care Med.* **195**, 1207–1215. <https://doi.org/10.1164/rccm.201605-0916OC> (2017).
12. Wilkes, A. R., Hodzovic, I. & Latto, I. P. Introducing new anaesthetic equipment into clinical practice. *Anaesthesia* **63**, 571–575. <https://doi.org/10.1111/j.1365-2044.2008.05583.x> (2008).
13. French-Mowat, E. & Burnett, J. How are medical devices regulated in the European Union?. *J. R. Soc. Med.* **105**(Suppl 1), S22–28. <https://doi.org/10.1258/jrsm.2012.120036> (2012).
14. Beck, J., Sinderby, C., Lindstrom, L. & Grassino, A. Crural diaphragm activation during dynamic contractions at various inspiratory flow rates. *J. Appl. Physiol.* **1985**(85), 451–458. <https://doi.org/10.1152/jappl.1998.85.2.451> (1998).
15. Volsko, T. A. Devices used for CPAP delivery. *Respir. Care* **64**, 723–734. <https://doi.org/10.4187/respcare.06625> (2019).
16. Cortegiani, A. *et al.* A new configuration for helmet continuous positive airway pressure allowing tidal volume monitoring. *Am. J. Respir. Crit. Care Med.* **202**, 612–614. <https://doi.org/10.1164/rccm.202003-0550LE> (2020).
17. Racca, F. *et al.* Helmet ventilation and carbon dioxide rebreathing: Effects of adding a leak at the helmet ports. *Intensive Care Med.* **34**, 1461–1468. <https://doi.org/10.1007/s00134-008-1120-x> (2008).
18. Glover, G. W. & Fletcher, S. J. Assessing the performance of the Whisperflow continuous positive airway pressure generator: A bench study. *Br. J. Anaesth.* **102**, 875–881. <https://doi.org/10.1093/bja/aep077> (2009).
19. Gibney, R. T., Wilson, R. S. & Pontoppidan, H. Comparison of work of breathing on high gas flow and demand valve continuous positive airway pressure systems. *Chest* **82**, 692–695. <https://doi.org/10.1378/chest.82.6.692> (1982).
20. Venus, B., Jacobs, H. K. & Lim, L. Treatment of the adult respiratory distress syndrome with continuous positive airway pressure. *Chest* **76**, 257–261. <https://doi.org/10.1378/chest.76.3.257> (1979).
21. Ricksten, S. E., Bengtsson, A., Soderberg, C., Thorden, M. & Kvist, H. Effects of periodic positive airway pressure by mask on postoperative pulmonary function. *Chest* **89**, 774–781. <https://doi.org/10.1378/chest.89.6.774> (1986).
22. Mistracchi, G. *et al.* Noninvasive CPAP with face mask: Comparison among new air-entrainment masks and the Boussignac valve. *Respir. Care* **58**, 305–312. <https://doi.org/10.4187/respcare.01598> (2013).
23. Beck, J. *et al.* Electrical activity of the diaphragm during pressure support ventilation in acute respiratory failure. *Am. J. Respir. Crit. Care Med.* **164**, 419–424. <https://doi.org/10.1164/ajrccm.164.3.2009018> (2001).
24. Gherini, S., Peters, R. M. & Virgilio, R. W. Mechanical work on the lungs and work of breathing with positive end-expiratory pressure and continuous positive airway pressure. *Chest* **76**, 251–256. <https://doi.org/10.1378/chest.76.3.251> (1979).
25. Vargas, M. *et al.* Performances of CPAP devices with an oronasal mask. *Respir. Care* **63**, 1033–1039. <https://doi.org/10.4187/respcare.05930> (2018).
26. Kroo, L. *et al.* Pneumask: Modified full-face snorkel masks as reusable personal protective equipment for hospital personnel. *medRxiv*. <https://doi.org/10.1101/2020.04.24.20078907> (2020).
27. Fraticelli, A. T. *et al.* Physiological effects of different interfaces during noninvasive ventilation for acute respiratory failure. *Crit. Care Med.* **37**, 939–945. <https://doi.org/10.1097/CCM.0b013e31819b575f> (2009).

Acknowledgements

The authors express gratitude to Prof. S. Cuzzocrea for providing the Charlotte Valve and to M.L. Noto for assistance in the drawing.

Author contributions

A.N., C.G. and C.C. conceived and designed the study. A.N., P.P., M.G. and F.B. collected the data. A.N. and P.P. developed the data analysis tools. A.N., P.P., A.C., A.Ca., L.A. performed the analysis. A.N., C.C., L.A., C.G. wrote the manuscript. All authors have critically revised the manuscript and approved the final version.

Funding

None.

Competing interests

Prof. Alberto Noto received honoraria for lectures from Edwards Lifescience (not relevant to this protocol). Dr. Cortegiani declares a patent pending, in association with the University of Palermo—Italy (N°102019000020532)—Italian Ministry of Economic Development), not discussed in the present study. Prof. Cesare Gregoretti declares a patent pending, in association with the University of Palermo—Italy (N°102019000020532)—Italian Ministry of Economic Development), not discussed in the present study. Prof. Gregoretti received honoraria for lectures or consultancies from Philips, Resmed, Vivisol, OrionPharma, Origin (not relevant to this protocol). All other authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to A.N.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021